Browse by category

Eli Lilly and Company has announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs. In 2020, Lilly partnered with the Trump Administration on a pilot programme that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programmes and millions more who pay out-of-pocket. U

Nitinotes has received CE Mark approval for the EndoZip System, the first fully automated suturing platform for endoscopic sleeve gastroplasty (ESG). The milestone clearance enables the company to begin commercialisation across the European Union and other CE Mark-accepting markets. Nitinotes will launch EndoZip in select European centres of excellence, building clinical adoption and real-world data to support broader market penetration. In parallel, the company is preparing

Researchers from the University of Liverpool, using the first modelled estimate to date shows how mandatory nutrition labelling could impact obesity prevalence and mortality in England's population, have found that making front-of-pack nutrition labelling mandatory could significantly reduce obesity rates and save thousands of lives across England. Using a microsimulation model, the team examined the effects of introducing either mandatory traffic light or nutrient warning la

For patients living with mild-to-moderate obesity, newer obesity management medications (OMM) such as tirzepatide and semaglutide, appear to be valid alternatives to endoscopic bariatric procedures (EBP) and metabolic bariatric surgery (MBS), according to researchers from the Italian Obesity Society (Società Italiana dell'Obesità (SIO)). Their study reveals the results from a systematic review (SR) and a network meta-analysis (NMA) on randomised clinical trials (RCTs) compari

Phenomix Sciences has announced results from new research, presented at Obesity Week 2025, demonstrating the continued clinical utility of its MyPhenome test, backed by a proprietary machine-learning Genetic Risk Score (GRS), in predicting obesity and treatment outcomes across large and diverse patient populations. The studies, led by Mayo Clinic researcher and Phenomix co-founder Dr Andres Acosta, further validate the MyPhenome test's ability to predict patient response to G

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including MBS is independently associated with improved survival in individuals aged 69 years and older, re-sleeve gastrectomy associated with significantly higher rates of serious perioperative complications, conversion to open in bariatric surgery associated with significant increased r